Cytokinetics (CYTK) Retained Earnings (2010 - 2026)

Cytokinetics (CYTK) has reported Retained Earnings for 17 consecutive years, with -$3.7 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 28.98% year-over-year to -$3.7 billion; the TTM figure through Mar 2026 stood at -$3.7 billion (down 28.98% YoY), while the FY2025 annual figure was $630000.0, up 100.02% from the prior year.
• Retained Earnings declined to -$3.7 billion in Q1 2026 per CYTK's latest filing, from $630000.0 in the prior quarter.
• Across five years, Retained Earnings topped out at $5.4 million in Q3 2024 and bottomed at -$3.7 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$1.6 billion across 5 years, with a median of -$1.6 billion in 2022.
• On a YoY basis, Retained Earnings climbed as much as 100.27% in 2024 and fell as far as 27017540.0% in 2024.
• Cytokinetics' Retained Earnings stood at -$1.6 billion in 2022, then surged by 100.0% to -$10000.0 in 2023, then slumped by 27017540.0% to -$2.7 billion in 2024, then jumped by 100.02% to $630000.0 in 2025, then sank by 586250.79% to -$3.7 billion in 2026.
• Business Quant data shows CYTK's Retained Earnings at -$3.7 billion in Q1 2026, $630000.0 in Q4 2025, and -$3.3 billion in Q3 2025.